Mateos, Maria-Victoria http://orcid.org/0000-0003-2390-1218
Weisel, Katja http://orcid.org/0000-0001-9422-6614
De Stefano, Valerio http://orcid.org/0000-0002-5178-5827
Goldschmidt, Hartmut http://orcid.org/0000-0003-0961-0035
Delforge, Michel
Mohty, Mohamad
Cavo, Michele http://orcid.org/0000-0003-4514-3227
Vij, Ravi
Lindsey-Hill, Joanne
Dytfeld, Dominik
Angelucci, Emanuele
Perrot, Aurore http://orcid.org/0000-0003-0131-8689
Benjamin, Reuben
van de Donk, Niels W. C. J.
Ocio, Enrique M.
Scheid, Christof
Gay, Francesca http://orcid.org/0000-0002-8619-412X
Roeloffzen, Wilfried
Rodriguez-Otero, Paula
Broijl, Annemiek
Potamianou, Anna
Sakabedoyan, Caline
Semerjian, Maria
Keim, Sofia
Strulev, Vadim
Schecter, Jordan M.
Vogel, Martin
Wapenaar, Robert
Nesheiwat, Tonia
San-Miguel, Jesus http://orcid.org/0000-0002-9183-4857
Sonneveld, Pieter http://orcid.org/0000-0002-0808-2237
Einsele, Hermann http://orcid.org/0000-0002-7680-0819
Moreau, Philippe
Funding for this research was provided by:
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.
Article History
Received: 30 November 2021
Revised: 4 February 2022
Accepted: 14 February 2022
First Online: 24 March 2022
Competing interests
: M-VM: honoraria/member on the board of directors/advisory committees (Amgen, Adaptive Biotechnologies, BMS Celgene, Janssen, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, Sea-Gen, Takeda). KW: honoraria (Roche); consultant/honoraria (Adaptive Biotech, Karyopharm, Takeda); honoraria/membership on board of directors/advisory committees (BMS, Celgene, Amgen, GSK, Janssen, Oncopeptides, Sanofi). VDS: honoraria (Abbvie, Alexion, Amgen, AOP Pharmaceutical, BMS Celgene, Grifols, GSK, Sanofi, SOBI, Takeda); honoraria/research funding (Novartis). HG: honoraria (GSK); consultant (Adaptive Biotech); research funding (Incyte, Johns Hopkins University, Molecular Partners, MSD, Mundipharma); honoraria/research funding (Novartis); honoraria/research funding (Chugai); consultant/ honoraria/research funding (Amgen, BMS, Celgene, Janssen, Sanofi). MD: honoraria/research funding (Amgen, Celgene, Janssen, Sanofi). MM: honoraria (Amgen, Astellas, BMS, Gilead, Takeda, Novartis, Pfizer, Adaptive Biotech); honoraria/research funding (Celgene, Sanofi). MC: honoraria (Novartis); honoraria/consultant (GSK, Adaptive Biotech); honoraria/consultant, membership on board of directors/advisory committees/speakers bureau (BMS, Sanofi, AbbVie, Amgen, Takeda); honoraria/consultant/member of board of directors/advisory and speakers bureaus/travel accommodations and expenses (Janssen, Celgene). DD: employee/consultant/ honoraria/member of board of directors/advisory committees (Janssen Cilag); member of board of directors/advisory committees/research funding (Celgene). AuP: honoraria (AbbVie, Amgen, BMS Celgene, GSK); honoraria/research funding (Sanofi); honoraria/member of board of directors/advisory committees (Janssen); honoraria/research funding/member of board of directors/advisory committees (Takeda). RB: honoraria/research funding (Allogene, Janssen, BMS, Gilead, Servier). NWCJvdD: research funding (Cellectis), consultant (Takeda, Roche, Novartis, Bayer, Servier); research funding/consultant (Janssen, Amgen); consultant/honoraria (BMS Celgene). EMO: consultant (Sanofi, Oncopeptides); consultant/honoraria (Janssen, Takeda); consultant/honoraria/research funding (Amgen, BMS Celgene). ChS: honoraria (AbbVie); consultant (Roche); honoraria/member of board of directors/advisory committees (Novartis, Takeda); consultant/honoraria/member of board of directors/advisory committees (Amgen, BMS, Janssen). FG: honoraria (BMS); consultant/honoraria (Sanofi); member of board of directors/advisory committees (Roche, Adaptive Biotech, Oncopeptides, Bluebird Bio); honoraria/member of board of directors/advisory committees (Amgen, Celgene, Janssen, Takeda, AbbVie, GSK). PR-O: honoraria/speaker bureaus (BMS Celgene, Janssen, Amgen, GSK, Sanofi, Regeneron, Oncopeptides). AB: honoraria (Amgen, BMS Celgene, Janssen, Sanofi). AnP, JMS: employees and holders of stock options at Janssen. CaS, MS, RW: employees of Janssen. SK: employee of Janssen R&D. VS: employee of Janssen Pharmaceutica NV. MV: employee of Janssen Global Services, LLC. TN: employee of Legend Biotech USA. JS-M: consultant/member of board of directors/advisory committees (AbbVie, Amgen, BMS Celgene, GSK, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Regeneron, Roche, Sanofi, Secura Bio, Takeda). PS: honoraria/research funding (SkylineDx); consultant/honoraria/research (Amgen, BMS Celgene, Janssen, Karyopharm, Takeda). PM: honoraria (AbbVie, Amgen, Janssen, Sanofi, Celgene/BMS, Oncopeptides). RV, JL-H, EA, WR, and HE: no relationships to disclose. Funded by Janssen Research & Development, LLC and Legend Biotech, Inc.; ClinicalTrials.gov identifier, NCT04035226.